PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
Por:
Pascual T, De Las Heras B, Martinez N, Oliveira M, Simon S, Lopez R, Cabrero I, Alarcon J, de Duenas E, Gimenez D, Cao M, Sanchez L, Murillo S, de Ceballos H, Cortes J, Cussac A, Prat A
Publicada:
1 may 2022
Ahead of Print:
1 may 2022
Resumen:
|